Intra-Cellular Therapies Inc $ 25.75 0.78 (3.12%)
Volume:
591,157
Avg Vol (1m):
2,472,879
Market Cap $:
2.03 Bil
Enterprise Value $:
1.65 Bil
P/E (TTM):
0.00
P/B:
4.51
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 16.23 | ||
| Equity-to-Asset | 0.86 | ||
| Debt-to-Equity | 0.07 | ||
| Debt-to-EBITDA | -0.13 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 16.3 | ||
| Beneish M-Score | 541.15 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -6296.39 | ||
| Net Margin % | -6114.98 | ||
| ROE % | -62.66 | ||
| ROA % | -52.89 | ||
| ROC (Joel Greenblatt) % | -918.39 | ||
| 3-Year Revenue Growth Rate | -50 | ||
| 3-Year EBITDA Growth Rate | -1.5 | ||
| 3-Year EPS without NRI Growth Rate | 0.1 |
ITCI
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 4.51 | ||
| PS Ratio | 547.88 | ||
| EV-to-EBIT | -8.58 | ||
| EV-to-EBITDA | -8.61 | ||
| EV-to-Revenue | 541.09 | ||
| Current Ratio | 10.4 | ||
| Quick Ratio | 10.34 | ||
| Days Inventory | 3434.32 | ||
| Days Sales Outstanding | 281.5 | ||
| Days Payable | 10089.12 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.53 | ||
| Earnings Yield (Greenblatt) % | -11.63 |